This monoclonal antibody J5-1 that is reactive with at least part of endotoxin core of Gram-negative bacteria may be effective in treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria.
Figure 1 depicts the binding in an ELISA assay of monoclonal antibodies obtained from a J5-1 hybridoma culture supernatant with purified Escherichia coli J5 endotoxin core.
Figure 2 shows the binding in an ELISA assay of monoclonal antibodies produced by a J5-1 ascites tumor with purified Escherichia coli J5 endotoxin core.
Figure 3 is a depiction of the results of a competitive inhibition ELISA assay illustrating a concentration-dependent inhibition of the specific binding activities of the J5-1 and J5-2 monoclonal antibodies by homologous and heterologous endotoxins.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1170-VHH | Recombinant Anti-endotoxin VHH Single Domain Antibody | Neut, ChiP, IP, FUNC | Llama VHH |
There are currently no Customer reviews or questions for TAB-348MZ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.